Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Authors
Keywords
-
Journal
Science Signaling
Volume 6, Issue 288, Pages ra68-ra68
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-08-14
DOI
10.1126/scisignal.2004008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans
- (2013) Susan F. Hudachek et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells
- (2012) Dhara N. Amin et al. BIOCHEMICAL JOURNAL
- Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks
- (2012) Daniel C Kirouac et al. BMC Systems Biology
- HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
- (2012) D. B. Vaught et al. CANCER RESEARCH
- CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set
- (2012) W. C. Reinhold et al. CANCER RESEARCH
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
- (2012) Michael J. Lee et al. CELL
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Navigating cancer network attractors for tumor-specific therapy
- (2012) Pau Creixell et al. NATURE BIOTECHNOLOGY
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Computational Approaches for Analyzing Information Flow in Biological Networks
- (2012) B. Kholodenko et al. Science Signaling
- Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
- (2012) H. M. Stern Science Translational Medicine
- Merging Systems Biology with Pharmacodynamics
- (2012) R. Iyengar et al. Science Translational Medicine
- Intratumor Heterogeneity: Seeing the Wood for the Trees
- (2012) T. A. Yap et al. Science Translational Medicine
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- (2011) Joan T. Garrett et al. CANCER BIOLOGY & THERAPY
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- (2011) Timothy R. Wilson et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Rapid Phospho-Turnover by Receptor Tyrosine Kinases Impacts Downstream Signaling and Drug Binding
- (2011) Laura B. Kleiman et al. MOLECULAR CELL
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
- (2011) C-R Pradeep et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli
- (2011) Melody K. Morris et al. PLoS Computational Biology
- Logic-Based Models for the Analysis of Cell Signaling Networks
- (2010) Melody K. Morris et al. BIOCHEMISTRY
- Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
- (2010) S. Iadevaia et al. CANCER RESEARCH
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Dynamic interaction networks in a hierarchically organized tissue
- (2010) Daniel C Kirouac et al. Molecular Systems Biology
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Towards genome-scale signalling-network reconstructions
- (2010) Daniel R. Hyduke et al. NATURE REVIEWS GENETICS
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
- (2010) D. N. Amin et al. Science Translational Medicine
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk
- (2009) Chun-Chao Wang et al. Molecular Systems Biology
- Cell–cell interaction networks regulate blood stem and progenitor cell fate
- (2009) Daniel C Kirouac et al. Molecular Systems Biology
- Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data
- (2009) William W Chen et al. Molecular Systems Biology
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data
- (2009) Alexander Mitsos et al. PLoS Computational Biology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now